POLOCAINE

Post-LOE

mepivacaine hydrochloride

Teva

ANDAINJECTIONINJECTABLE

Approved

Aug 1984

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

POLOCAINE (mepivacaine hydrochloride) by Teva is clinical pharmacology: local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 1984.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY: Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general,…

Worked on POLOCAINE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

POLOCAINE

Mechanism of Action

Indications